Condition
Attention Deficit-Hyperactivity
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (1)
P 4 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03945175Phase 3CompletedPrimary
Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening
NCT00205699Phase 4Completed
Metabolic Effects of Antipsychotics in Children
NCT03546010Not ApplicableUnknownPrimary
Oculometry as an Attentional Mechanism Evaluation Tool and Attention Deficit Hyperactivity Inhibition
Showing all 3 trials